Quick Facts

• A 2025 study found creatine supplementation reduced colitis severity and prevented depression-like symptoms in animal models
• IBD patients have lower levels of creatine transporter in gut tissue, which may contribute to reduced barrier function
• Large population study showed each tenfold increase in dietary creatine intake linked to 19% lower risk of chronic constipation

Creatine, long known for muscle and brain benefits, shows new promise for gut health in inflammatory bowel disease patients, according to emerging research.

A groundbreaking 2025 study published in Food & Function found that rats with chronic colitis experienced reduced symptom severity after oral creatine supplementation. The treatment also prevented motor deficits, anxiety, and depression-like behaviors throughout chronic colitis development.

The research builds on a comprehensive review published in Nutrition Research suggesting creatine demonstrates significant antioxidant and anti-inflammatory activity. The supplement shows therapeutic potential in restoring intestinal homeostasis.

Energy Crisis in the Gut

The gut uses up to 20 percent of all cellular energy to maintain barrier function. Colon tissues from IBD patients show reduced levels of creatine transporter messenger RNA compared to healthy individuals.

“Mucosal biopsy specimens from patients with ulcerative colitis and inactive Crohn’s disease have lower levels of CRT, which might contribute to the reduced barrier function observed in patients with IBD,” researchers noted.

Creatine supports ATP regeneration and enhances mitochondrial function. This helps preserve the integrity of epithelial cells lining the gut.

Population-Level Evidence

A large NHANES analysis revealed promising population-level data. Each tenfold increase in dietary creatine intake was associated with a 19% lower risk of chronic constipation.

Chronic diarrhea affects 4-5% of the global population, while chronic constipation affects 10-15% of adults. These conditions significantly impact quality of life and healthcare costs.

Clinical Trial Progress

The NCT02463305 trial protocol tested 7g twice daily for eight weeks. A current pilot clinical trial at the University of Colorado is investigating oral creatine at 2 × 7g per day over two months in mild to moderate ulcerative colitis patients.

Preliminary data suggests micronized forms may reduce gastrointestinal side effects by 54%. Pilot outcomes show a 22% reduction in CRP levels compared to placebo.

A notable 2016 case study documented “a patient with Crohn’s ileitis achieved symptom resolution after reintroducing 1g/day of creatine and discontinuing medication.”

Microbiome Benefits

Creatine helps preserve anaerobic conditions required for beneficial bacteria. By enabling epithelial cells to maintain oxygen consumption, it supports butyrate-producing microbes like Faecalibacterium and Roseburia.

Individual studies indicate creatine supplementation is generally well tolerated without clinically significant side effects. Experts recommend 3-5g daily as a maintenance dose.

Current evidence relies heavily on preclinical models, with only 17% of studies involving humans. More clinical trials are needed to determine optimal dosing and safety profiles for gut health applications.

Read more: Creatine For Gut Health? What A New Reveals For Inflammatory Conditions